Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...
Combination therapy
Akeso Biopharma Completes Enrollment for AK112 Phase III Study
China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...
Hengrui’s Pyrotinib Granted Breakthrough Therapy Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Hengrui Medicine Co., Ltd’s (SHA:...
Ascletis Signs Pact with Pfizer China for Ritonavir Tablets
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co., Ltd has...
HutchMed Initiates Phase II/III Study for Elunate and Tyvyt in Renal Cell Carcinoma
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase...
InxMed and Huaota Bio Partner to Develop Novel Solid Tumor Combination Therapy
China-based InxMed (Nanjing) Co., Ltd has entered into a strategic partnership with Shanghai Huaota Biopharmaceutical...
Covis Pharma’s COPD Therapies Show Positive Results in Phase III AVANT Trial
Luxembourg-based Covis Pharma Group has released positive topline data from its Phase III AVANT trial,...
Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China
The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...
China Approves GSK’s Juluca for HIV-1 Infection
The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...
Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study
China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...
Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study
China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership...
Hotgen Biotech Gains Regulatory Approvals in Saudi Arabia and India
China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving one certificate from the Saudi...
BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its Bruton’s...
BeiGene Partners with Immune-Onc for Clinical Development of Myeloid Checkpoint Inhibitors
China-based biotech BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a clinical study...
Hengrui Medicine’s Pyrotinib Filing Accepted for Review by NMPA
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its supplementary market filing...
Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...
I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial
China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...
Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval...
Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study...
Henlius Biotech’s PD-1 Inhibitor Serplulimab Secures NMPA Review for Esophageal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...